WuXi Biologics (Cayman) Inc. has announced a strategic collaboration with Virogen Biotechnology Inc. to advance the development and commercialization of VG712, Virogen's lead clinical-stage asset. Under this partnership, WuXi Biologics will provide comprehensive services, including technology transfer, process validation, and commercial manufacturing for both the drug substance and drug product of VG712. This collaboration aims to accelerate VG712's path to global market approval. VG712, a first-in-class anti-CD3 immunotoxin, is designed to restore immune function by depleting the patient's existing T cell pool, a strategy known as immunological reset. The drug has received Fast Track designation from the U.S. Food and Drug Administration, and a pivotal Phase II trial is currently underway. A Biologics License Application submission is anticipated between 2027 and 2028. No results from this trial have been presented yet.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。